Investigational First-Line Combination Treatment for EGFR-Mutant Lung Cancers
Combining osimertinib and bevacizumab appears to be a tolerable first-line treatment for patients with epidermal growth factor receptor (EGFR)-mutant lung cancers, according to data from an ongoing phase I/II study. Helena Yu, MD, of Memorial Sloan Kettering Cancer Center, presented these findings at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9033).
From September 2016 to January 2017, 15 patients were enrolled in the study. The investigators administered full doses of osimertinib (80 mg/day) and bevacizumab (15 mg/kg every 3 weeks), with a planned dose de-escalation in the event of grade 3 or higher toxicity.
After a median duration of treatment of 2.7 months, no dose-limiting toxicities were seen in any patient, and the maximum tolerated doses were determined to remain unchanged at 80 mg/day osimertinib and bevacizumab at 15 mg/kg every 3 weeks. A total of 43 patients will be treated at that dose in the phase II study, with a primary endpoint of progression-free survival at 12 months.
To date, all 15 patients remain in the study and are being treated at the maximum tolerated dose. The investigators reported that all treatment-related adverse events have been mild (grade 1/2), except for grade 3 hypertension, and efficacy assessment is ongoing.